The global infertility drugs market size was valued at US$ 3,699.8 million in the year 2023 and is projected to grow to US$ 6,814.68 million by 2033. This market is expected to register a CAGR of 6.3% during the analysis period. Due to the increase in infertility, a rise in the demand for infertility drugs is expected to emerge.
Infertility affects both men and women equally. The causes of female infertility include growing older, polycystic ovarian syndrome (PCOS), obesity, and miscarriages. While the causes of male infertility include erectile dysfunction, low sperm count, abnormal sperm, and others. The BGU developed a new treatment that re-lengthens telomeres to protect cells by stimulating telomerase expression.
For treating infertility, market players are focused on introducing novel medications. A firm is currently developing the first-in-class OXO-001 product candidate, which is expected to enhance the binding of embryos to the inner lining of the uterus by increasing binding strength. In addition, Ferring Pharmaceuticals has recently launched a novel fertility treatment for women, Trisequens.
๐ฎ๐๐ ๐ณ๐๐๐๐๐ ๐บ๐๐๐๐๐ ๐ช๐๐๐@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16593
Key Takeaways from Market Study
Competitive Landscape:
Several prominent companies dominate this market, including Ferring Pharmaceuticals Inc., Merck KGaA, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Theramex, Novartis AG., Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co., Mankind Pharma Ltd., and others.
๐จ๐๐ ๐จ๐ ๐จ๐๐๐๐๐๐@ https://www.futuremarketinsights.com/ask-question/rep-gb-16593
Sustainable and environmental footprint awareness may drive the choice of active ingredients and materials for the Infertility Drug Market, as well as packaging. By engaging in these activities, manufacturers can expand their product portfolios, expand their geographical reach, and capture a larger share of the market.
In addition to gaining access to the latest markets and advanced technologies, key players can also gain access to new markets by partnering with other companies. In addition, companies can acquire, merge, and diversify their portfolios.
Recent Developments:
๐ฉ๐๐ ๐ต๐๐/๐ท๐๐๐๐๐๐๐@ https://www.futuremarketinsights.com/checkout/16593
Infertility Drugs Market Segmentation by Category
By Drug Class:
By End User:
By Distribution Channel:
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries:ย sales@futuremarketinsights.com
Website:ย https://www.futuremarketinsights.com
LinkedIn|ย Twitter|ย Blogs
The post Combined Sales of Infertility Drugs Market Will Cross US$ 6,814.68 million by 2033; Ovulation Disorder is Leading to a Rise in Demand for Infertility Drugs. appeared first on Future Market Insights.